FR2389375A1 - - Google Patents

Info

Publication number
FR2389375A1
FR2389375A1 FR7813047A FR7813047A FR2389375A1 FR 2389375 A1 FR2389375 A1 FR 2389375A1 FR 7813047 A FR7813047 A FR 7813047A FR 7813047 A FR7813047 A FR 7813047A FR 2389375 A1 FR2389375 A1 FR 2389375A1
Authority
FR
France
Prior art keywords
pgi2
analogue
prostaglandin
arteriosclerosis
thrombosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7813047A
Other languages
English (en)
French (fr)
Other versions
FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of FR2389375A1 publication Critical patent/FR2389375A1/fr
Application granted granted Critical
Publication of FR2389375B1 publication Critical patent/FR2389375B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
FR7813047A 1977-05-06 1978-05-03 Expired FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5127877A JPS53136513A (en) 1977-05-06 1977-05-06 Stabilization of prostaglandin-x-related compounds

Publications (2)

Publication Number Publication Date
FR2389375A1 true FR2389375A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-12-01
FR2389375B1 FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-08-06

Family

ID=12882465

Family Applications (2)

Application Number Title Priority Date Filing Date
FR7813047A Expired FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-05-06 1978-05-03
FR7831038A Granted FR2398498A1 (fr) 1977-05-06 1978-11-02 Compositions stabilisees a usage pharmacologique contenant un analogue de la prostaglandine i2

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR7831038A Granted FR2398498A1 (fr) 1977-05-06 1978-11-02 Compositions stabilisees a usage pharmacologique contenant un analogue de la prostaglandine i2

Country Status (5)

Country Link
US (1) US4479944A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS53136513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2819447A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (2) FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB1604162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0016610A3 (en) * 1979-03-19 1981-08-05 American Cyanamid Company Method for preserving an e-type prostaglandin and stabilized pge-type in triethyl citrate solution

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-09-23 1982-08-28
DE2811950A1 (de) * 1978-03-18 1979-12-13 Hoechst Ag Neue analoga von prostacyclin
US4430340A (en) * 1978-07-17 1984-02-07 The Upjohn Company Stabilization of PGI2 compounds with surfactants
DE2902809A1 (de) 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
US4303671A (en) 1980-07-10 1981-12-01 The Upjohn Company Albumin stabilized prostacyclin
JPS6013779A (ja) * 1983-07-05 1985-01-24 Green Cross Corp:The プロスタグランジンｉ↓２誘導体
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
JP5925158B2 (ja) * 2013-06-04 2016-05-25 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829579A (en) * 1971-11-01 1974-08-13 Upjohn Co Stable solutions of pge-type compounds
FR2362833A1 (fr) * 1976-02-04 1978-03-24 Upjohn Co Nouveaux derives 5 de prostaglandine, leur procede de preparation et medicament les contenant
FR2367497A1 (fr) * 1976-10-12 1978-05-12 Wellcome Found Association medicamenteuse comprenant une prostaglandine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1970-06-10 1975-02-04
DE2357953A1 (de) * 1973-11-21 1975-05-28 Hoechst Ag Neue, natuerlich nicht vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US4070537A (en) * 1975-05-30 1978-01-24 Ono Pharmaceutical Company 17-Oxo-17-phenyl-prostaglandins
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
HU179141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1977-09-23 1982-08-28
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829579A (en) * 1971-11-01 1974-08-13 Upjohn Co Stable solutions of pge-type compounds
FR2362833A1 (fr) * 1976-02-04 1978-03-24 Upjohn Co Nouveaux derives 5 de prostaglandine, leur procede de preparation et medicament les contenant
FR2367497A1 (fr) * 1976-10-12 1978-05-12 Wellcome Found Association medicamenteuse comprenant une prostaglandine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0016610A3 (en) * 1979-03-19 1981-08-05 American Cyanamid Company Method for preserving an e-type prostaglandin and stabilized pge-type in triethyl citrate solution

Also Published As

Publication number Publication date
FR2389375B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-08-06
FR2398498A1 (fr) 1979-02-23
GB1604162A (en) 1981-12-02
JPS53136513A (en) 1978-11-29
FR2398498B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-12-17
US4479944A (en) 1984-10-30
GB1604161A (en) 1981-12-02
DE2819447A1 (de) 1978-11-09

Similar Documents

Publication Publication Date Title
FR2389375A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2419758A1 (fr) Composition de gel
BE821093A (fr) Compositions detergentes utiles pour la solubilisation des huiles et des graisses
ES443422A1 (es) Un procedimiento para la preparacion de una composicion far-ceutica que contiene una 2-descarboxi-2-(tetrazol-5-il)-11- desoxi-gamma-pentanorprostaglandina.
AR207877A1 (es) Procedimiento para la produccion de trasplantes heterologos de arterias
FR2358394A1 (fr) Nouveaux esters de l'hydroxysuccinimide, des procedes pour leur fabrication et leur utilisation
FR2445319A1 (fr) Derives de pyridine, procedes pour leur preparation et compositions pharmaceutiques les contenant
IT8521325A0 (it) Benzammidi sostituite farmacologicamente attive utili per il trattamento della emesi da chemioterapia.
ES423870A1 (es) Procedimiento para la obtencion de enonas.
NL7705591A (nl) Werkwijze ter bereiding van reukstofcomposities onder toepassing van alifatische 2-methyl-2-al- kyl-alkaanzuuresters alsmede aldus bereide reuk- stofcomposities.
FR2453851A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
BE891639A (fr) Compositions pharmaceutiques contenant de la gamma-butyro-betaine pour le traitement de syndromes provoques par une deficience en l-carnitine
ES455104A1 (es) Un procedimiento para la preparacion de d-homoesteroides.
FR2361877A1 (fr) Nouvelles lactones d'acides libres du type prostaglandine, leur preparation et medicament les contenant
ES436613A1 (es) Un procedimiento para la preparacion de una composicion far-maceutica estabilizada.
BE810780A (fr) Perfectionnements relatifs a la preparation des huiles lubrifiantes
IT1020169B (it) Composizioni di oli lubrificanti
IT1136568B (it) Composizioni per l'idratazione delle sostanze cheratiniche,costutuite da solfossidi di alfa-ammino-acidi
BE845709R (fr) Composition pharmaceutique contenant du 1, 3-bis (2-carboxychromone-5-yloxy)-2-hydroxypropane pour le traitement de l'ulcere de la bouche
BE856740A (fr) Nouvelle composition medicamenteuse pour le traitement de la lithiase biliaire
SE7909105L (sv) Farmaceutiska kompositioner pa basis av aryltrifluoretanol
FR2422667A1 (fr) Derives de 7a-methoxycephalosporine, leur procede de preparation et leur application en therapeutique
FR2387216A2 (fr) Nouveaux derives substitues de 9-desoxy-9-methylene prostaglandines et compositions pharmaceutiques en contenant
IT1033053B (it) Procedimento per la fabbricazione di acido levulinico da alcool furfurilico
BE899366A (fr) Compositions pharmaceutiques topiques a base d'acide meclophenamique.

Legal Events

Date Code Title Description
ST Notification of lapse